Literature DB >> 24202232

Lifetime incidence risk of alopecia areata estimated at 2.1% by Rochester Epidemiology Project, 1990-2009.

Sultan A Mirzoyev1, Adam G Schrum2, Mark D P Davis1, Rochelle R Torgerson3.   

Abstract

Entities:  

Mesh:

Year:  2013        PMID: 24202232      PMCID: PMC3961558          DOI: 10.1038/jid.2013.464

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


× No keyword cloud information.

Letter

Alopecia Areata (AA) is characterized by patchy, nonscarring, autoimmune-mediated hair loss, although many aspects of AA pathogenesis are unknown (Gilhar ). The scalp is most commonly involved in clinically treated AA, but any hair-bearing surface of the body may be affected (Wasserman ). Males and females of any age and hair color can have AA (Finner, 2011; Kyriakis ). According to the First National Health and Nutrition Examination Survey conducted in the early 1970s, AA is fairly common; it was estimated to affect about 2 of every 1,000 people in the United States (Safavi, 1992). Dermatologists encounter AA in 0.7% to 4.0% of their patient populations (Price, 1991; Sharma ; Tan ). A previous study reported by Mayo Clinic and National Institutes of Health (Safavi ) showed that the overall incidence of AA in Olmsted County, Minnesota, was 20.2 per 100,000 person-years from 1975 through 1989. A similar incidence rate for both sexes with a lifetime risk of 1.7% was observed. The purpose of the current study was to continue the previous analysis and document the most current lifetime incidence risk of AA. Clinical data accessed via the Rochester Epidemiology Project (REP) provided a retrospective review of all patients resident in Olmsted County, Minnesota, that were newly diagnosed with AA from 1990 through 2009. Of 530 qualifying patients, the mean age at diagnosis was 33.6 years (median, 33 years; range, 0–90 years). Additional features for the study cohort are summarized in Table 1. The mean age at diagnosis of AA for males was 31.5 years (median, 31 years; range, 0.5–80 years); for females, it was 36.2 years (median, 36.4 years; range, 1.8–90.7 years).
Table 1

Patient Characteristics (N=530)

CharacteristicNumber of Patients (%)
Year of diagnosis (n=530)
 1990–199490 (17)
 1995–1999120 (23)
 2000–2004149 (28)
 2005–2009171 (32)
Female sex271 (51)
Diagnosis
 Dermatologist460 (87)
 Nondermatologist physician70 (13)
Biopsy confirmationa73 (14)
Race (n=482)
 White423 (88)
 Asian30 (6)
 Black18 (4)
 Hispanic or Latino11 (2)

All biopsy results were confirmed by dermatologists.

As shown in Table 2, the age- and sex-adjusted incidence of AA was 20.9 per 100,000 person-years (95% CI, 19.1–22.6). Cumulative AA incidence increased almost linearly with age (0.3%, 20 years; 0.6%, 30 years; 0.8%, 40 years; 1.1%, 50 years; 1.4%, 60 years), while cumulative lifetime incidence was 2.1%. Age-adjusted incidence was 21.3 per 100,000 person-years (95% CI, 18.8–23.9) for females and 20.2 per 100,000 person-years (95% CI, 17.7–22.6) for males (no significant difference, P = 0.77), supporting the observation that both females and males display similar susceptibility to AA.
Table 2

Incidence of AA in Olmsted County, Minnesota, 1990–2009, Stratified by Age and Sex

Females
Males
Total
Age at DiagnosisNo. of PatientsRateaNo. of PatientsRateaNo. of PatientsRatea
 0–92714.93216.75915.8
 10–193319.42614.65917.0
 20–294927.15832.910729.9
 30–394523.17337.211830.1
 40–495227.13619.28823.2
 50–593525.42418.15921.8
≥603014.3106.44010.9
Total27121.3b25920.2b53020.9c

Incidence rates per 100,000 person-years.

Incidence rates per 100,000 person-years were age-adjusted to the 2000 US white population.

Incidence rates per 100,000 person-years were age- and sex-adjusted to the 2000 US white population.

At 2.1%, the cumulative lifetime incidence of AA from this recent 20-year period (1990–2009) was slightly higher than 1.7% observed in the older study (years 1975–1989) (Safavi ). Similarly, REP data analyzed in studies of other autoimmune-associated diseases have shown that incidence of rheumatoid arthritis (Myasoedova ) and systemic lupus erythematosis (Uramoto ) have also increased in the region in recent years. These data do not refute the hypothesis that autoimmune disease incidence may be rising, generally. The current study also confirms that AA does not exhibit a gender bias (Muller and Winkelmann, 1963). Although some studies have reported AA to be slightly more common in females (Goh ; Kyriakis ; Tan ), such findings might be attributable to a greater cultural awareness of and sensitivity to hair loss among females that prompts them to seek medical attention. Interestingly, in Turkey, a higher male: female ratio (1.6:1) was reported for patients with AA (Kavak ). The authors explained the likely artificial skew toward male patients in the context of religious practices and suggested that the headscarves worn by women may have allowed some to avoid seeking medical attention for hair loss. The predominantly white patient population in the current study is reflective of the geographic race distribution and is not a sign of racial differences in AA prevalence. In conclusion, we assessed the incidence of AA in Olmsted County, Minnesota, during a recent 20-year period (1990–2009), and found that the lifetime incidence risk was 2.1%.

Methods

Clinical Setting

This study was approved by the institutional review boards of Mayo Clinic and Olmsted Medical Center. The REP medical records system links information from all health care providers in Olmsted County, Minnesota. It includes medical records for all residents of the county, regardless of where care was received in the county. The relative geographic isolation of Olmsted County residents from other medical institutions provides a unique opportunity to conduct population-based analyses (St Sauver ).

Patient Selection

The REP databank was used to identify Olmsted County residents with their first lifetime diagnosis of AA established from 1990 through 2009. Medical records of identified patients were reviewed and data were abstracted. Each diagnosis was validated by a physician and documented in the medical record.

Statistical Methods

Incidence rates per 100,000 person-years were calculated using incident cases of AA as the numerator and age- and sex-specific estimates of the county population as the denominator. The populations at risk for the years 1990–2000 were estimated using census data from 1990 and 2000, with linear interpolation for intercensal years. The populations at risk for the years 2001–2009 were obtained from US Intercensal Estimates (United States Census Bureau). Because the population of Olmsted County is nearly all white, incidence rates were directly age- and sex-adjusted to the structure of the 2000 US white population. Incident cases were grouped on the basis of age at diagnosis (0–9, 10–19, 20–29, 30–39, 40–49, 50–59, and ≥60 years) and year of diagnosis (1990–1994–1995–1999–2000–2004, and 2005–2009). The relationships of age at diagnosis, sex, and year of diagnosis with the incidence of AA were assessed by fitting Poisson regression models using the SAS procedure GENMOD (SAS Institute Inc). P values less than 0.05 were considered statistically significant.
  15 in total

1.  ALOPECIA AREATA. AN EVALUATION OF 736 PATIENTS.

Authors:  S A MULLER; R K WINKELMANN
Journal:  Arch Dermatol       Date:  1963-09

2.  Prevalence of alopecia areata in the First National Health and Nutrition Examination Survey.

Authors:  K Safavi
Journal:  Arch Dermatol       Date:  1992-05

Review 3.  Alopecia areata.

Authors:  Dan Wasserman; Daniela Araucaria Guzman-Sanchez; Kimberly Scott; Amy McMichael
Journal:  Int J Dermatol       Date:  2007-02       Impact factor: 2.736

4.  Alopecia areata prevalence by gender and age.

Authors:  K P Kyriakis; K Paltatzidou; E Kosma; E Sofouri; A Tadros; E Rachioti
Journal:  J Eur Acad Dermatol Venereol       Date:  2008-09-03       Impact factor: 6.166

5.  Data resource profile: the Rochester Epidemiology Project (REP) medical records-linkage system.

Authors:  Jennifer L St Sauver; Brandon R Grossardt; Barbara P Yawn; L Joseph Melton; Joshua J Pankratz; Scott M Brue; Walter A Rocca
Journal:  Int J Epidemiol       Date:  2012-11-18       Impact factor: 7.196

6.  Profile of 513 patients with alopecia areata: associations of disease subtypes with atopy, autoimmune disease and positive family history.

Authors:  C Goh; M Finkel; P J Christos; A A Sinha
Journal:  J Eur Acad Dermatol Venereol       Date:  2006-10       Impact factor: 6.166

7.  The pattern and profile of alopecia areata in Singapore--a study of 219 Asians.

Authors:  Eileen Tan; Yong-Kwang Tay; Chee-Leok Goh; Yoke Chin Giam
Journal:  Int J Dermatol       Date:  2002-11       Impact factor: 2.736

8.  Profile of alopecia areata in Northern India.

Authors:  V K Sharma; G Dawn; B Kumar
Journal:  Int J Dermatol       Date:  1996-01       Impact factor: 2.736

9.  Trends in the incidence and mortality of systemic lupus erythematosus, 1950-1992.

Authors:  K M Uramoto; C J Michet; J Thumboo; J Sunku; W M O'Fallon; S E Gabriel
Journal:  Arthritis Rheum       Date:  1999-01

10.  Incidence of alopecia areata in Olmsted County, Minnesota, 1975 through 1989.

Authors:  K H Safavi; S A Muller; V J Suman; A N Moshell; L J Melton
Journal:  Mayo Clin Proc       Date:  1995-07       Impact factor: 7.616

View more
  43 in total

Review 1.  The role of lymphocytes in the development and treatment of alopecia areata.

Authors:  Hongwei Guo; Yabin Cheng; Jerry Shapiro; Kevin McElwee
Journal:  Expert Rev Clin Immunol       Date:  2015-09-07       Impact factor: 4.473

2.  Integrative analysis of rare copy number variants and gene expression data in alopecia areata implicates an aetiological role for autophagy.

Authors:  Lynn Petukhova; Aakash V Patel; Rachel K Rigo; Li Bian; Miguel Verbitsky; Simone Sanna-Cherchi; Stephanie O Erjavec; Alexa R Abdelaziz; Jane E Cerise; Ali Jabbari; Angela M Christiano
Journal:  Exp Dermatol       Date:  2019-07-09       Impact factor: 3.960

Review 3.  Bitemporal Scalp Hair Loss: Differential Diagnosis of Nonscarring and Scarring Conditions.

Authors:  Brianna De Souza; Andrea Tovar-Garza; Laura N Uwakwe; Amy McMichael
Journal:  J Clin Aesthet Dermatol       Date:  2021-02-01

Review 4.  A review of monochromatic light devices for the treatment of alopecia areata.

Authors:  Evan Darwin; Harleen Arora; Penelope A Hirt; Tongyu Cao Wikramanayake; Joaquin J Jimenez
Journal:  Lasers Med Sci       Date:  2017-12-17       Impact factor: 3.161

5.  Topographic Phenotypes of Alopecia Areata and Development of a Prognostic Prediction Model and Grading System: A Cluster Analysis.

Authors:  Solam Lee; Beom Jun Kim; Chung-Hyeok Lee; Won-Soo Lee
Journal:  JAMA Dermatol       Date:  2019-05-01       Impact factor: 10.282

Review 6.  Alopecia areata.

Authors:  C Herbert Pratt; Lloyd E King; Andrew G Messenger; Angela M Christiano; John P Sundberg
Journal:  Nat Rev Dis Primers       Date:  2017-03-16       Impact factor: 52.329

Review 7.  Incidence of diseases primarily affecting the skin by age group: population-based epidemiologic study in Olmsted County, Minnesota, and comparison with age-specific incidence rates worldwide.

Authors:  Laurel L Wessman; Louise K Andersen; Mark D P Davis
Journal:  Int J Dermatol       Date:  2018-01-29       Impact factor: 2.736

Review 8.  Alopecia areata: Animal models illuminate autoimmune pathogenesis and novel immunotherapeutic strategies.

Authors:  Amos Gilhar; Adam G Schrum; Amos Etzioni; Herman Waldmann; Ralf Paus
Journal:  Autoimmun Rev       Date:  2016-03-10       Impact factor: 9.754

Review 9.  Sex differences in the incidence of skin and skin-related diseases in Olmsted County, Minnesota, United States, and a comparison with other rates published worldwide.

Authors:  Louise K Andersen; Mark D P Davis
Journal:  Int J Dermatol       Date:  2016-03-24       Impact factor: 2.736

10.  Maternal IL-6 can cause T-cell-mediated juvenile alopecia by non-scarring follicular dystrophy in mice.

Authors:  Stephen E P Smith; Rachel L G Maus; Tessa R Davis; John P Sundberg; Diana Gil; Adam G Schrum
Journal:  Exp Dermatol       Date:  2016-02-10       Impact factor: 3.960

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.